Computational analysis of epigenetic patterns facilitates diagnosis of unknown hereditary disorders
A new sophisticated computational model, developed by scientists at Lawson Health Research Institute, is bringing an innovative method of diagnosing rare hereditary conditions.
Genome-wide testing of DNA methylation, a mechanism of the epigenome, has been shown to facilitate the diagnosis of previously unsolved cases of neurodevelopmental or congenital abnormalities. The epigenome is any process that can change the expression of a gene without changing the gene sequence.
The latest in a series of research publications around the theme of epigenomic testing applied the new pattern recognition model to DNA samples of 965 patients with neurodevelopmental and congenital anomalies that did not have a definitive diagnosis despite extensive clinical genetic testing. Their DNA, acquired through blood samples, was examined using the new model, and dozens of new cases were resolved.
Current testing of patients who present with neurodevelopmental and congenital anomalies leaves a number of cases undiagnosed or unexplained. “Many families spend years going through repeated testing and assessments, in search of a diagnosis. This process is hard on patients and families, and is a great cost to our health care system,” explains Dr. Bekim Sadikovic, Associate Scientist at Lawson, and Head of the Molecular Genetics Division in the Department of Pathology and Laboratory Medicine, London Health Sciences Centre (LHSC).
While currently there are limited treatment options associated with many of these conditions, providing a specific diagnosis can help physicians better predict the course of the disease, allowing for better planning and support for the patient. This research highlights the value of epigenomic testing in the routine assessment of neurodevelopmental and congenital disorders.
From this research, LHSC will be the first site in the world to offer this type of genetic testing. “We are excited to make this testing accessible to local patients, and across the world. Our lab has partnered and licensed this technology to Greenwood Genetics Laboratories in the United States and Amsterdam University Medical Centre Laboratories in the European Union”, says Dr. Sadikovic. 100 per cent of revenue will be funneled back to support local testing for patients and ongoing research.
Learn more: Research leads to new molecular diagnostic tool
The Latest on: Molecular diagnostic tool
via Google News
The Latest on: Molecular diagnostic tool
- Gene-editing tool CRISPR wins the chemistry Nobelon October 7, 2020 at 3:11 pm
A gene-editing tool developed just eight years ago that has “revolutionized the life sciences” nabbed the 2020 Nobel Prize in chemistry.
- 2 women earn Chemistry Nobel Prize for gene-editing tool CRISPRon October 7, 2020 at 8:58 am
Nobel Prize in chemistry went to two women who developed a gene-editing tool called CRISPR-Cas9, which snips DNA like a pair of molecular scissors. The technique "has not ...
- Meridian Bioscience Launches a Complete Solution to Support Liquid Biopsy Cancer Diagnosticson October 7, 2020 at 6:15 am
(GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a complete ...
- Global Companion Animal Diagnostic Market Set For Rapid Growth, To Reach Value Around USD 2,833 Million By 2024on October 6, 2020 at 2:26 pm
Zion Market Research has published a new report titled “Companion Animal Diagnostic Market by Companion Animal (Dogs, Cats, Equine, and Others) and by Technology (Immunodiagnostics [ELISA, Lateral ...
- CLEAR and Quest Diagnostics Collaborate to Integrate COVID-19 Test Results with "Health Pass" for Safer Environmentson October 5, 2020 at 12:15 pm
CLEAR, the secure identity company, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information ...
- Quidel Receives Emergency Authorization for First Rapid Antigen "ABC Test": A Combination Diagnostic Assay for Influenza A+B and COVID-19on October 2, 2020 at 4:19 pm
Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has ...
- KASTURBA MOLECULAR DIAGNOSTIC LABORATORYon October 2, 2020 at 12:50 am
"This initial tranche of funding will seek to further strengthen and support the Government of India’s efforts to increase laboratory capacity for SARS-COV-2 testing, including molecular diagnostics ...
- Digital PCR as a Universal Molecular Diagnostic Standardon September 30, 2020 at 2:13 pm
As a result, it is difficult for research laboratories and diagnostics ... molecular laboratories and hospitals around the world. Read more about the process of establishing digital PCR as an ...
- DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic That Predicts COVID-19 Severity Riskon September 29, 2020 at 10:05 pm
Inflammatix received a DARPA grant worth $1.1M for a COVID-19 severity risk test which outperformed IL-6 and other biomarkers in a new study.
- Veterinary Molecular Diagnostics Market Size, Growth, Opportunity, Forecast and Covid-19 Impact Analysis to 2025on September 28, 2020 at 8:40 pm
Global Veterinary Molecular Diagnostics Market was valued at USD 2.46 Billion in 2018, and is estimated to reach at USD ...
via Bing News